Granted Patent
B2
US 12,371,663 · App. 17/493,685 · Granted Jul 29, 2025
Engineered γδ T-cells
Inventors:
Aya Jakobovits (Beverly Hills, CA); Orit Foord (Foster City, CA); Andy An-deh Lin (Palo Alto, CA); Marianne Theresa Santaguida (Belmont, CA)
Assignee:
ADICET THERAPEUTICS, INC.
C12N5/0636A61K40/11A61K40/31A61K40/32A61K40/42A61K40/4205A61K40/4211A61K40/4212A61K40/4222A61K40/4255A61K40/4266A61K40/4274C07K14/70503C12N15/00C07K14/70539C12N2501/2302C12N2501/515C12N2501/599C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to engineered γδ T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered γδ T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered γδ T-cell(s) populations to therapeutically useful quantities. An engineered γδ T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.
Claims (18)
1. An ex vivo method for producing an expanded δ2 γδ T-cell population, comprising:
a) providing a sample of a human subject, wherein the sample comprises γδ T-cells,
b) selectively expanding the δ2 γδ T-cells by culturing cells of the sample in the presence of at least one antibody which selectively expands the δ2 γδ T-cells to produce a culture comprising the expanded δ2 γδ T-cell population;
wherein said at least one antibody which selectively expands δ2 γδ T-cells is selected from B6 or 15D antibodies which bind to a specific epitope of a δ2 TCR chain, to selectively expand δ2 γδ T-cells; and
wherein the culture comprising the expanded γδ T-cell population comprises a percentage of δ2 γδ T-cells, wherein the percentage of δ2 γδ T-cells is greater than 60% of total viable cells of the culture, optionally wherein the percentage of δ2 γδ T-cells is greater than 80%, or 90%, optionally, of total viable cells of the culture, and wherein the expanded γδ T-cell population comprises at least about 1×10 7 δ2 γδ T-cells.
2. The method of claim 1 , wherein said method does not comprise expanding the γδ T-cell population by an antigen presenting cell, an aminophosphate, or a nitrogen containing bisphosphonate.
3. The method of claim 1 , wherein said at least one antibody which selectively expands δ2 γδ T-cells are immobilized on a surface.
4. The method of claim 1 , wherein said sample is selected from a peripheral blood sample, a cord blood sample or a tumor.
5. The method of claim 1 , wherein the expanded γδ T-cell population is further formulated for administration to a subject.
6. The method of claim 1 , wherein the expanded γδ T-cell population includes a therapeutically effective amount of γδ T-cells.
7. The method of claim 6 , wherein the expanded γδ T-cell population is engineered to stably express one or more tumor recognition moieties.
8. The method of claim 1 , further comprising selectively expanding the 82 γδ T-cells by culturing cells of the sample in the presence of a cytokine selected from IL-2, IL-7, IL-9, IL-12, IL-15, IL-18, IL-21, and IL-33.
9. The method of claim 8 , wherein said cytokine is selected from the group consisting of IL-2, IL-7, IL-15, and IL-21.
10. The method of claim 9 , wherein said cytokine is selected from the group consisting of IL-2, IL-7, and IL-15.
11. The method of claim 1 , further comprising:
enriching the γδ T-cells prior to selectively expanding the δ2 γδ T-cells.
12. The method of claim 11 , wherein the enriching includes removing one or more of red blood cells, NK cells, αβ cells, B cells, monocytes, and macrophages.
13. The method of claim 1 , wherein the sample comprises a whole PBMC population without prior depletion of monocytes, αβ T-cells, B-cells, and NK cells.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 19, 2024
From: JAKOBOVITS, AYA; FOORD, ORIT; LIN, ANDY AN-DEH; SANTAGUIDA, MARIANNE THERESA
To: ADICET BIO, INC.
Reel/Frame 067169/0900 →
CHANGE OF NAME
Recorded Dec 6, 2022
From: ADICET BIO, INC.
To: ADICET THERAPEUTICS, INC.
Reel/Frame 062002/0241 →
Continuity (3)
Provisional Application
62080500
· Nov 17, 2014
References Cited (122)
US 5185250A
· Brenner et al.
· 1993
[cited by applicant]
US 5260223A
· Brenner et al.
· 1993
[cited by applicant]
US 7728114B2
· Mach et al.
· 2010
[cited by applicant]
US 7985739B2
· Kay et al.
· 2011
[cited by applicant]
US 9540448B2
· Scheinberg et al.
· 2017
[cited by applicant]
US 20030138433A1
· Newell et al.
· 2003
[cited by applicant]
US 20060122130A1
· Rabbani
· 2006
[cited by applicant]
US 20060205089A1
· Dratz et al.
· 2006
[cited by applicant]
US 20080026986A1
· Wang et al.
· 2008
[cited by applicant]
US 20100272739A1
· Gelfand et al.
· 2010
[cited by applicant]
US 20120034221A1
· Bonvini et al.
· 2012
[cited by applicant]
US 20150259645A1
· Poupot et al.
· 2015
[cited by applicant]
CN 1506456A
· 2004
[cited by applicant]
CN 102994448A
· 2013
[cited by applicant]
WO WO1993020221A1
· 1993
[cited by applicant]
WO WO2001022816A1
· 2001
[cited by applicant]
WO WO2003087341A2
· 2003
[cited by applicant]
WO WO2011090804A1
· 2011
[cited by applicant]
WO WO2012012667A2
· 2012
[cited by applicant]
WO WO2012156958A2
· 2012
[cited by applicant]
WO WO2013074916A1
· 2013
[cited by applicant]
WO WO2013079174A1
· 2013
[cited by applicant]
WO WO2014009370A2
· 2014
[cited by applicant]
WO WO2014134412A1
· 2014
[cited by applicant]
WO WO2015061694A2
· 2015
[cited by examiner]
WO WO2015156673A2
· 2015
[cited by applicant]
WO WO2016081518A2
· 2016
[cited by applicant]
WO WO2016198480A1
· 2016
[cited by applicant]
WO WO2017011804A1
· 2017
[cited by applicant]
D'Asaro et al. (J Immunol (2010) 184 (6): 3260-3268). (Year: 2010).
[cited by examiner]
Ness-Schwickerath et al. (Immunol (2010) 184 (12): 7268-7280). (Year: 2010).
[cited by examiner]
Ali et al, “γδ T Cell Immune Manipulatino during Chroinic Phase of Simian HIV Infection Confers Immunological Benefits”, J. Immunol., vol. 183, No. 8, pp. 5407-5417 (2009).
[cited by applicant]
Appay et al., “Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections,” Nature Medicine, vol. 8, pp. 379-385 (2002).
[cited by applicant]
Avdalovic et al., “Adhesion and costimulation of proliferative responses of human γδ T cells by interaction of VLA-4 and VLA-5 with fibronectin”, Immunology Letters, vol. 35, No. 2, pp. 101-108 (1993).
[cited by applicant]
Bauer et al., Gene Therapey for HIV: From Inception 49 to a Possible Cure, SpringBriefs in Biochemistry and Molecular Biology, Chapter 7, pp. 49-54 (2014).
[cited by applicant]
BioCompare, “Monoclonal Antibody Anti-Human TCR PAN [gamma]/[delta] PN IM1349—Purified—Freeze-dried—0.1 mg—Clone IMMU510 for Research Use Only. Not for use in diagnostic procedures”, Beckman Coulter: Jan. 1, 2006, p. 1,…
[cited by applicant]
Bornstein et al, “Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies,” Investigational New Drugs., Vo. 28, Issue 5, pp. 561-574 (2010).
[cited by applicant]
Boucherma et al., “HLA-A*01:03, HLA-A*24-02, HLA-B8:08-01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 Monochain Transgenic/H-2 Class I Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses,…
[cited by applicant]
Carding and Egan, “γδ Tcells: Functional Plasticity and Heterogeneity,” Nat Rev Immunol vol. 2, pp. 336-345 (2002).
[cited by applicant]
Cheever et al., “The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research,” Clin. Cancer Res., vol. 15(17), pp. 5323-5337 (2009).
[cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J. Mol. Biol. vol. 293, pp. 865-881 (1999).
[cited by applicant]
Chothia and Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., vol. 196, pp. 901-917 (1987).
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, vol. 342, pp. 878-883 (1989).
[cited by applicant]
Ciccone, “A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31-lymphocytes to express their functional program(s)”, The Journal of Experimental Med…
[cited by applicant]
Dao et al. “Targeting the intracellular WT1 oncogene product with a therapeutic human antibody” Science translational medicine, vol. 5(176): 176ra33, pp. 1-22 (2013).
[cited by applicant]
Damschroder et al., “Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies,” Mol Immunol, vol. 41(10) pp. 985-1000 (2004).
[cited by applicant]
Daubenberger et al., “Functional and Structural Similarity of Vγ9V δ2 T Cells in Humans and Aotus Monkeys, a Primate Infection Model for Plasmodium falciparum Malaria,” J Immunol, vol. 167, pp. 6421-6430 (2001).
[cited by applicant]
Davis and Merwe, “The structure and ligand interactions of CD2: implications for T-cell function,” Immunol. Today, vol. 17, Issue 4, pp. 177-187 (1996).
[cited by applicant]
Deniger et al., “Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor,” Molecular Therapy, vol. 21, No. 3, pp. 638-647 (2013).
[cited by applicant]
Deniger et al., “Clinical applications of gamma delta T cells with multivalent immunity” Front. & Immunology, vol. 5, pp. 1-12 (2014).
[cited by applicant]
Dohan & Reiter, “T-cell-receptor-like antibodies—generation, function and applications,” Expert Rev Mol Med., vol. 14(e6), pp. 1-17 (2012).
[cited by applicant]
Dokouhaki et al, Adoptive immunotherapy of cancer using ex vivo expanded human γδ T cells: A new approach, Cancer Letters, vol. 297, pp. 126-136 (2010).
[cited by applicant]
Edwards et al, “The Remarkable Flexibility of theHuman Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS”, J. Mol. Biol., vol. 334, pp. 102-118 (2003).
[cited by applicant]
Ehl et al., “A variant of SCID with specific immune responses and predominance of gamma delta T cells”, J. of Clinical Investigation, vol. 115, No. 11, pp. 3140-3148 (2005).
[cited by applicant]
Fisher et al., “Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells,” Clinical Cancer Research, vol. 20, No. 22, pp. 5720-5732 (2014).
[cited by applicant]
Gonzalez et al., “Humanized mice: novel model for studying mechanisms of human immune-based therapies,” Immunol. Res. vol. 57, pp. 326-334 (2013).
[cited by applicant]
Gra et al., “Analysis of T-Cell Receptor-γ Gene Rearrangements Using Oligonucleotide Microchip: A Novel Approach for the Determination of T-Cell Clonality,” Journal of Molecular Diagnostics, vol. 9, No. 2 pp. 249-257 (2…
[cited by applicant]
Green, et al., “Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin”, Clin Exp Immunol., vol. 136(3), pp. 472-482 (2004).
[cited by applicant]
Groh et al., “Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB,” PNAS, vol. 96, pp. 6879-6884 (1999).
[cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, vol. 63, pp. 446-448 (1993).
[cited by applicant]
Harlow et al. Antibodies, A Laboratory Manual, Cold Spring Harbor laboratory, pp. 37-47 (1988).
[cited by applicant]
Hayday A.C., “γδ Cells: A Right Time and Right Place for a Conserved Third Way of Protection,” Annu Rev Immunol. vol. 18, pp. 975-1026 (2000).
[cited by applicant]
Hayday and Pennington, “Key factors in the organized chaos of early T cell development,” Nature Immunology. vol. 8, No. pp. 137-144 (2007).
[cited by applicant]
Hiasa et al., “Dual specificity of αβ-γδ TCR T cells: transformation of Vγ9Vδ2 T cells with MAGE-A4143-151 specific αβ type TCR genes,” Annual Meeting of the Japanese Cancer Association, vol. 66, p. 423 (2007).
[cited by applicant]
Hua et al., “Potentinal regulatory role of in vitro-expanded Vδ1 T cells from human peripheral blood,” Immunol Res. vol. 56, pp. 172-180 (2013).
[cited by applicant]
Jakobovits et al., “Production of fully human antibodies by transgenic mice,” Curr. Opin. Biotechnol., vol. 6, Issue 5, pp. 561-566 (1995).
[cited by applicant]
Janssens et al., “Generation of heavy-chain-only antibodies in mice,” PNAS, vol. 103, No. 41, pp. 15130-15135 (2006).
[cited by applicant]
Jin et al., “Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia,” Journal of Hematology & Oncology vol. 9:126, pp. 1-7 (2016).
[cited by applicant]
Kabelitz et al., “The primary response of human gamma/delta+ T cells to
[cited by applicant]
Kabelitz and He, “The Multifunctionality of Human Vγ9Vδ2 γδ T Cells: Clonal Plasticity or Distinct Subsets? : Plasticity of Human γδ T Cells,” Scandinavian Journal of Immunology, vol. 76, pp. 213-222 (2012).
[cited by applicant]
Kang et al., “Adoptive immunotherapy of lung cancer with immobilized anti-TCRγδ antibody-expanded human γδ T-cells in peripheral blood,” Cancer Biology & Therapy, vol. 8, Issue 16, pp. 1540-1549 (2009).
[cited by applicant]
Kim and Hong, “Humanization by CDR Grafting and Specificity-Determining Residue Grafting,” Methods in Molecular Biology, vol. 907, pp. 237-245 (2012).
[cited by applicant]
Klebanoff et al, “CD8+ T-cell memory in tumor immunology and immunotherapy,” Immunol Rev., vol. 211, pp. 214-224 (2006).
[cited by applicant]
Kress et al., Distinct gene expression in human Vδ1 and Vδ2 γδ T cells following non-TCR agonist stimulation, Molecular Immunology, vol. 43, pp. 2002-2011 (2006).
[cited by applicant]
Kondo et al., “Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy,” Cytotherapy, vol. 10, No. 8, pp. 842-856 (2008).
[cited by applicant]
Lamb and Lopez, “γδ T cells: A New Frontier for Immunotherapy?,” Biology of Blood and Marrow Transplantation, vol. 11, pp. 161-168 (2005).
[cited by applicant]
Lang et al., “Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma,” Cancer Immunol Immunother, vol. 60, pp. 1447-1460 (2011).
[cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, vol. 27, pp. 55-77 (2003).
[cited by applicant]
Li et al, “Transgenic mice with a diverse human T cell antigen receptor repertoire,” Nature Med.vol. 16, pp. 1029-1035 (2010).
[cited by applicant]
Lloyd et al, “Modelling the human immune response: perfomance of a 10
[cited by applicant]
Lopez et al., “CD2-mediated IL0120dependent signals render human-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the de…
[cited by applicant]
Luoma et al., “γδ T cell surveillance via CD1 molecules,” Trens in Immunolgoy, vol. 35, No. 12, pp. 613-621 (2014).
[cited by applicant]
Malmborg et al., “BIAcore as a tool in antibody engineering,” J. Immunol. Methods, vol. 183, pp. 7-13 (1995).
[cited by applicant]
Mangan et al., “Cutting Edge: CD1d Restriction and Th1/Th2/Th17 Cytokine Secretion by Human V 3 T Cells,” J. of Immunol., vol. 191, pp. 30-34 (2013).
[cited by applicant]
Michie et al., “Lifespan of human lymphocyte subsets defined by CD45 isoforms,” Nature, vol. 360, pp. 364-365 (1992).
[cited by applicant]
Moonka and Loh, “A consensus primer to amplify both α and β chains of the human T cell receptor,” Journal of Immunological Methods, vol. 169, pp. 41-51 (1994).
[cited by applicant]
Nagamine et al., Induction of γδ T Cells Using Zoledronate Plus Interleukin-2 in Patients with Metastatic Cancer, Hiroshima J. Med. Sci, vol. 58, No. 2, pp. 37-44 (2009).
[cited by applicant]
Nakajima et al., “A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γ≡ T cells,” European Journal of Cardio-thoracic Surgery, vol. 37, pp. 1191-1197 (2010).
[cited by applicant]
Nicol et al., “Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours,” British Journal of Cancer, vol. 105, pp. 778-786 (2011).
[cited by applicant]
Nussbaumer et al., “Essential Requirements of Zoledronate-Induced Cytokine and γδ T Cell Proliferative Responses,”, J. of Immunol., vol. 191, No. 3, pp. 1346-1355 (2013).
[cited by applicant]
Oberg et al., “γδ T cell activation by bispecific antibodies,” Cellular Immunology, vol. 296, pp. 41-49 (2015).
[cited by applicant]
Petros et al., “Improved analysis of TCR γδ variable region expression in humans,” Journal of Immunological Methods, vol. 434, pp. 66-72 (2016).
[cited by applicant]
Peyrat et al., “Repertoire analysis of human peripheral blood lymphocytes using a human V delta 3 region-specific monoclonal antibody. Characterization of dual T cell receptor (TCR) delta-chain expressors and alpha beta…
[cited by applicant]
Qi et al., “Immobilized MICA Could Expand Human Vδ1 γδT Cells In Vitro that Displayed Major Histocompatibility Complex Class I Chain-Related A—Dependent Cytotoxicity to Human Epithelial Carcinomas.” Scandinavian Journal…
[cited by applicant]
Rei et al., “The Emerging Protumor Role of γδ T Lymphocytes: Implications for Cancer Immunotherapy,” Cancer Research, vol. 75(5), pp. 798-802 (2015).
[cited by applicant]
Romagne F et al, “Structural analysis of gammadelta TCR using a novel set of TCR gamma and delta chain-specific monoclonal antibodies generated against soluble gammadelta TCR Evidence for a specific conformation adopted…
[cited by applicant]
Sagar et al., “In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: Implication for dendritic cell-based anti-HTLV-1 vaccine,” Vaccine, vol. 32, , pp. 3274-3284 (2014).
[cited by applicant]
Saitoh et al., “Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma,” Med Oncol., vol. 25, pp. 137-147 (2008).
[cited by applicant]
Sallusto et al., “Two subsets of memory T lymphocytes with distinct homing potentials and effector functions,” Nature, vol. 401, p. 708-712 (1999).
[cited by applicant]
Scheinberg et al., “Reaching Un-Drugable Intracellular Targets with the Long Arm of Antibodies,” Oncotarget, vol. 4(5), pp. 647-648 (2013).
[cited by applicant]
Scheper et al., “Hunting for clinical translation with innate-like immune cells and their receptors”, Leukemia, vol. 28, No. 6, pp. 1181-1190 (2014).
[cited by applicant]
Shang et al., “Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues,” European Journal of Immunology, vol. 39, pp. 2248-2258 (2009).
[cited by applicant]
Sheriff and Constantine, “Redefining the minimal antigen-binding fragment,” Nature Struct. Biol., vol. 3, No. 9, pp. 733-736 (1996).
[cited by applicant]
Siegers et al., “Human V delta 1 gamma delta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells”, Cytoherapy, vol. 13, No. 6, pp. 753-764 (2011…
[cited by applicant]
Siegers et al., “Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI”, Cancer Immunol. Immunother, vol. 62(3), pp. 571-58…
[cited by applicant]
Taupin et al., “An enlarged subpopulation of T lymphocytes bearing two distinct [gamma][delta] TCR in an HIV-positive patient”, International Immunology, vol. 11, No. 4, pp. 545-552 (1999).
[cited by applicant]
Vantourout et al., “Specific requirements for Vγ9Vδ2 T cell stimulation by a natural adenylated photphoantigen”, J. Immunol., vol. 183(6), pp. 3848-3857 (2009).
[cited by applicant]
Weidanz et al., “TCR-Like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells,” Int. Rev. Immunol., vol. 30, pp. 328-340 (2011).
[cited by applicant]
Wild et al., “Dependence of T Cell Antigen Recognition on the Dimensions of an Accessory Receptor-Ligand Complex,” J. Exp. Med, vol. 190, No. 1, pp. 31-41 (1999).
[cited by applicant]
Wilhelm et al., “γδ T cells for immune therapy of patients with lymphoid malignancies,” Blood, vol. 102, No. 1, pp. 200-206 (2003).
[cited by applicant]
Wilhelm et al., “Successful adoptive transfer and in vivo expansion of haploidentical γδ T Cells,” J Transl Med., vol. 12, pp. 1-6 (2014).
[cited by applicant]
Wistuba-Hamprecht K, Pawelec G, Derhovanessian E. OMIP-020: phenotypic characterization of human γδ T-cells by multicolor flow cytometry. Cytometry A., vol. 85(6) pp. 522-524 (2014).
[cited by applicant]
Wu et al., “Ex vivo expanded human circulating Vδ1 γδ T cells exhibit favorable therapeutic potential for colon cancer,” Oncoimmunology, vol. 4:3, pp. e992749-e992813 (2015).
[cited by applicant]
Xu et al., “Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities,” Immunity, vol. 13, pp. 37-45 (2000).
[cited by applicant]
Yin, et al., “Hyperactivation and in situ recruitment of inflammatory Vγ2 T cells contributes to disease pathogensissi in systemic lupus erythematosus,”, Scientific Reports 5:14432, pp. 1-12 (2015).
[cited by applicant]
Yoon et al., “The Cell Cycle Time of CD8+ T Cells Responding In Vivo Is Controlled by the Type of Antigenic Stimulus,” PLOS One, vol. 5(11), pp. 1-12 (2010).
[cited by applicant]
Yu et al., “Expansion and Immunological Study of Human Tumor Infiltrating Gamma-Delta T Lymphocytes in vitro,” Int Arch Allergy Immunol, vol. 119, pp. 31-37 (1999).
[cited by applicant]
Zapata et al., “Engineering linear F(ab')2 fragments for efficient production in
[cited by applicant]
Zhou et al., “Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies,” Cellular & Molecular Immunology, vol. 9, pp. 34-44 (2012).
[cited by applicant]